Date: 2012-04-25
Type of information:
phase: 1
Announcement: submission of a Clinical Trial Application (CTA)
Company: Boehringer Ingelheim (Germany)
Product: undisclosed Nanobody®
Action mechanism: Nanobodies are antibody-derived therapeutic proteins that contain the unique structural and functional properties of naturally-occurring heavy-chain antibodies. The Nanobody® technology was originally developed following the discovery that camelidae (camels and llamas) possess fully functional antibodies that lack light chains. These heavy-chain antibodies contain a single variable domain (VHH) and two constant domains (CH2 and CH3). Importantly, the cloned and isolated VHH domain is a perfectly stable polypeptide harbouring the full antigen-binding capacity of the original heavy-chain antibody. These newly discovered VHH domains with their unique structural and functional properties form the basis of a new generation of therapeutic antibodies which Ablynx has named Nanobodies.
Disease: Alzheimer\'s disease
Therapeutic area: Neurodegenerative diseases
Country:
Trial details:
Latest
news: Ablynx has announced that Boehringer Ingelheim has submitted a Clinical Trials Application (CTA) to the European regulatory authorities to start a Phase I clinical trial with a Nanobody® for the treatment of Alzheimer\'s disease. The Nanobody has been developed as part of the collaboration signed between Ablynx and Boehringer and the event triggers a €1 million milestone payment to Ablynx.
In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer\'s disease using Ablynx\'s Nanobodies against a single disease target. The collaboration has a potential value of $265 million in upfront and milestone payments plus undisclosed royalties on product sales. Boehringer Ingelheim is solely responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration.
